Brought to you by 
Peptor enters diabetes collaboration with Aventis; ends
09 Sep 2014
Executive Summary
Aventis Pharma Germany and Peptor Ltd. (drugs to treat autoimmune diseases and cancer) will develop and sell DiaPep277 for the prevention and treatment of latent autoimmune diabetes in adults and Type I diabetes.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Peptor enters diabetes collaboration with Aventis; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice